API | rozanolixizumab

rozanolixizumab (RYSTIGGO) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA Priority Review ^FDA

AACT

Active Ingredient History

NOW

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- IgG receptor FcRn large subunit p51 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

ucb7665

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (1)

Myasthenia Gravis (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Fibromyalgia (Phase 2)

Glioma (Phase 2)

Glycemic Control (Phase 3)

Healthy Volunteers (Phase 1)

Myasthenia Gravis (Phase 3)

Polyradiculoneuropathy (Phase 2)

Thrombocytopenia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 22
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue